CRISPR Therapeutics AG ($CRSP) Stock Forecast: Down 5.1% Today

What is CRISPR Therapeutics AG?

CRSP (CRISPR Therapeutics) is a biotech company known for gene editing technologies. The market sentiment for CRSP has been bearish today.

Why is CRISPR Therapeutics AG going down?

CRSP stock is down 5.1% on Dec 3, 2024 18:42

• Analysts project a potential upside of 58.3% for CRSP.
• Earnings estimate revisions show a positive trend, hinting at potential future stock growth.
• Despite optimistic analyst outlook, CRSP's stock witnessed a bearish movement today, signaling a discrepancy between predictions and market performance.

CRSP Price Chart

CRSP Technical Analysis

CRSP News

Wall Street Analysts Think CRISPR Therapeutics ( CRSP ) Could Surge 58.3%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 58.3% in CRISPR Therapeutics (CRSP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

https://www.zacks.com/stock/news/2377933/wall-street-analysts-think-crispr-therapeutics-crsp-could-surge-583-read-this-before-placing-a-bet

Trending Today

Horizen ($ZEN) Crypto Forecast: Up 21.1% Today

Conflux ($CFX) Crypto Forecast: Up 8.3% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 6.3% Today

Dogecoin ($DOGE) Crypto Forecast: Up 6.8% Today

XRP ($XRP) Crypto Forecast: Up 7.2% Today

Bitcoin ($BTC) Crypto Forecast: Up 6.2% Today

Natural Gas ($GAS) Commodity Forecast: Up 7.1% Today

MicroStrategy ($MSTR) Stock Forecast: Up 5.4% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Up 7.0% Today

BlackBerry Limited ($BB) Stock Forecast: Up 6.6% Today

CRISPR Therapeutics AG Price History

13.08.2024 - CRSP Stock was up 5.4%

• The bullish movement in CRSP today can be attributed to:
• CRISPR Therapeutics AG settling at $45.51, representing a +1.42% change from its previous close, indicating positive investor sentiment.
• The ongoing advancements and developments in CRISPR gene-editing technology, driving optimism about the company's future prospects.
• Increased investor confidence in the biotech sector as a whole, leading to a surge in demand for CRSP shares.

03.11.2024 - CRSP Stock was down 5.1%

• Analysts project a potential upside of 58.3% for CRSP.
• Earnings estimate revisions show a positive trend, hinting at potential future stock growth.
• Despite optimistic analyst outlook, CRSP's stock witnessed a bearish movement today, signaling a discrepancy between predictions and market performance.

11.09.2024 - CRSP Stock was up 3.4%

• CRSP stock experienced a bullish movement likely due to positive developments in the gene-editing field and potential breakthroughs in CRISPR technology.
• The decision to sell Moderna stock might have redirected investor focus towards CRISPR-based companies like CRISPR Therapeutics, contributing to the bullish trend.
• The market movement could also be influenced by increasing investor confidence in CRSP's pipeline of gene therapies and potential for future growth in the biotech sector.
• Overall, the shift in portfolio and positive industry outlook may have fueled optimism around CRSP, leading to its strong bullish performance today.

28.09.2024 - CRSP Stock was up 1.6%

• CRISPR Therapeutics AG (CRSP) displayed a bullish movement, diverging from the general market direction.
• Investors were likely encouraged by the anticipated Q3 earnings, especially the sales performance of its gene therapy Casgevy.
• Despite recent fluctuations, CRSP's favorable trajectory could be linked to growing investor confidence in its pioneering gene-based treatments.
• The market's positive reception of CRSP's potential for expansion may have eclipsed broader market patterns, contributing to its upward momentum.

20.08.2024 - CRSP Stock was down 5.3%

• CRSP stock slid more than the broader market, indicating specific company-related factors contributing to the decline.
• The slight decrease in stock price could be due to profit-taking by investors after a recent uptrend or concerns about the company's future growth prospects.
• Market fluctuations and overall sentiment may have also played a role in the stock's bearish movement.
• Investors should closely monitor any upcoming company announcements or industry developments that could impact CRSP's stock performance in the near future.

23.09.2024 - CRSP Stock was down 5.1%

• The downward movement in CRISPR Therapeutics AG (CRSP) may be due to investors taking profits following a recent upturn.
• The potential decrease in CRISPR Therapeutics AG (CRSP) could have been influenced by a major investment firm reducing its stakes in other companies, causing a broader negative market sentiment.
• Despite optimistic forecasts by financial analysts for CRISPR Therapeutics AG (CRSP), current market conditions and profit-taking behaviors likely outweighed the positive outlook, leading to the bearish movement observed today.

11.10.2024 - CRSP Stock was up 6.2%

• Analysts are optimistic about CRISPR Therapeutics, with a mean price target suggesting a significant upside potential of 62.8% in the stock.
• Despite mixed third-quarter results, including a narrower loss than expected and sales missing estimates, the progress in the commercial launch of Casgevy, the first CRISPR-based gene therapy, is a positive indicator for the company's future growth prospects.
• The bullish movement in CRSP today could be attributed to the overall positive sentiment from analysts regarding the company's potential and the advancements in its groundbreaking gene-editing technology.

05.10.2024 - CRSP Stock was down 5.6%

• The strong bearish movement in CRSP today could be attributed to profit-taking by investors after the stock recently surpassed both the 20-day and 50-day moving averages.
• Some investors who closely follow technical analysis may have seen these moving average milestones as potential signals to sell, leading to a temporary downturn in the stock price.
• Despite the bearish movement, the long-term outlook for CRSP remains positive, given its innovative technologies and promising pipeline of gene-based therapies.

05.07.2024 - CRSP Stock was up 5.2%

• CRISPR Therapeutics (CRSP) observed a significant uptrend today, likely influenced by the positive sentiment across the biotech industry.
• Speculations around CRISPR Therapeutics emerging as a high-profit opportunity and the general upbeat outlook on biotech stocks may have fueled the positive movement.
• Emphasis on cutting-edge drugs and the potential for substantial returns in biotech may have further instilled confidence in CRSP among investors.
• The resurgence of biotech stocks, symbolized by the performance of the biotech ETF, together with the expectation of groundbreaking investments in genomics and precision therapeutics, may have facilitated the favorable conditions for CRSP's upward trend.

06.07.2024 - CRSP Stock was up 6.1%

• CRISPR Therapeutics (CRSP) stock experienced a strong bullish movement.
• Despite beating EPS expectations, the company missed revenue estimates for Q2 2024.
• The positive sentiment around CRISPR Therapeutics could be attributed to the potential of becoming a millionaire-maker stock, given its recent transition to a commercial-stage company.
• The overall positive outlook for biotech stocks, including CRSP, amidst a market environment where investors are turning back to the sector for growth opportunities, especially considering their resilience in downturns and potential for groundbreaking drug developments.

07.07.2024 - CRSP Stock was down 5.4%

• Following the Q2 2024 earnings release, CRSP stock showed a downward trend after surpassing EPS expectations but falling short of revenue forecasts by a significant amount.
• Despite being an established company with high growth potential, the lower-than-expected revenue results likely impacted investor confidence.
• The divergence between EPS and revenue performance could signify operational hurdles or slower revenue generation, prompting a sell-off of CRSP stock.
• Investors who were drawn in by the excitement surrounding gene-editing may have swiftly responded to the revenue shortfall, underscoring the volatility of biotech stocks and the significance of financial fundamentals in influencing stock prices.

15.07.2024 - CRSP Stock was up 5.0%

• CRISPR Therapeutics (CRSP) experienced a strong bullish movement today.
• The bullish trend could be attributed to the overall positive sentiment in the biotech industry, with a focus on gene editing stocks.
• The market is optimistic about CRISPR Therapeutics' potential to transform medicine and address genetic disorders.
• The company's recent regulatory approvals and advancements in gene-editing technology likely contributed to investor confidence and drove the stock price higher.